logo
搜索
菜单

intravenou的搜索结果

当前1/3页
排序: 最近更新
Using Eggs from Schistosoma mansoni as an In vivo Model of Helminth-induced Lung Inflammation 10.3791/3905-v 09:58 min
Using Eggs from Schistosoma mansoni as an In vivo Model of Helminth-induced Lung Inflammation
16.3: Endocarditis III: Medical Management 01:18 min
16.3: Endocarditis III: Medical Management
Methods for Intravenous Self Administration in a Mouse Model 10.3791/3739-v
Methods for Intravenous Self Administration in a Mouse Model
16.14: Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices 01:28 min
16.14: Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
15.3: Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship 01:14 min
15.3: Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
15.2: Pharmacokinetic–Pharmacodynamic Relationship: Dose to Pharmacological Effect 01:28 min
15.2: Pharmacokinetic–Pharmacodynamic Relationship: Dose to Pharmacological Effect
13.22: Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant 01:25 min
13.22: Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
12.13: IV Infusion to Oral Dosing: Conversion Methods 01:28 min
12.13: IV Infusion to Oral Dosing: Conversion Methods
12.13: IV Infusion to Oral Dosing: Conversion Methods 01:28 min
12.13: IV Infusion to Oral Dosing: Conversion Methods
12.11: Determination of Multiple Dosing Parameters: Loading and Maintenance Doses 01:25 min
12.11: Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
12.11: Determination of Multiple Dosing Parameters: Loading and Maintenance Doses 01:25 min
12.11: Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
12.9: Drug Accumulation During Multiple Dosing: Intermittent IV Infusions 01:24 min
12.9: Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
11.2: Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence 01:22 min
11.2: Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
9.1: Bioavailability: Overview 01:17 min
9.1: Bioavailability: Overview
The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice 10.3791/3644-v
The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
8.7: Parameters Affecting Nonlinear Elimination: Zero-Order Input, First-Order Absorption and Two-Compartment Model 01:13 min
8.7: Parameters Affecting Nonlinear Elimination: Zero-Order Input, First-Order Absorption and Two-Compartment Model
7.29: Noncompartmental Analysis: Miscellaneous Pharmacokinetic Parameters 00:54 min
7.29: Noncompartmental Analysis: Miscellaneous Pharmacokinetic Parameters
7.27: Noncompartmental Analysis: Mean Residence Time 01:05 min
7.27: Noncompartmental Analysis: Mean Residence Time
6.15: Clearance Models: Noncompartmental Models 01:17 min
6.15: Clearance Models: Noncompartmental Models
3.5: Drug Delivery: Parenteral Route 01:29 min
3.5: Drug Delivery: Parenteral Route
返回顶部